American Express (AXP) has jumped 9% today after reporting better-than-expected earnings, and since it’s a component of the Dow Jones Industrial Average, you’d expect the blue-chip benchmark to be soaring. You’d be wrong, thanks toTravelers Companies (TRV), which has tumbled 5.2% after reporting earnings of its own.
Now Travelers has a market cap of $33.2 billion, compared to American Express’ $56.6 billion market capitalization. The Dow, however, is price weighted, which means that the higher the price, the greater the stock weighting. American Express is trading at $66.77, while Travelers is trading at $110.22. That makes the move in Travelers count nearly twice as much as the one in American Express. Travelers has subtracted 41.16 points from the Dow Jones Industrial Average, while American Express has added 37.80 points.
- [By Monica Gerson]
Zions Bancorporation (NASDAQ: ZION) is estimated to post its quarterly earnings at $0.39 per share on revenue of $576.49 million. Zions Bancorporation shares gained 2.10 percent to close at $27.28 on Friday.
- [By Ben Levisohn]
Lee offers 22 stocks that could benefit from the correlation trade: Western Digital (WDC), Xerox (XRX), First Solar, Ford Motor, Best Buy (BBY), PulteGroup (PHM), AutoNation (AN), Textron (TXT), Jacobs Engineering Group (JEC), Mosaic, BB&T (BBT), Fifth Third Bancorp (FITB),Loews (L), Regions Financial (RF), KeyCorp (KEY), Comerica (CMA), Leucadia National (LUK), Zions Bancorp (ZION), Valero Energy (VLO), Marathon Oil, Cardinal Health (CAH), and Pepco Holdings (POM).
- [By Jon C. Ogg]
In the super-regional banks that are not money center banks, Regions Financial Corp. (NYSE: RF) was up 6.3% at $13.22, and Zions Bancorporation (NASDAQ: ZION) was last seen up 3.8% at $38.30. They would both do better with lower regulatory costs and be able to better compete against larger banks when their stress test results had not been as strong.
- [By Ben Levisohn]
Who will have the most incremental capital return? We would highlight Zions Bancorporation (ZION), Citigroup, Bank of America, and M&T Bank (MTB) as the CCAR banks that we expect to post the most material year-to-year increase in capital return in CCAR 2016.
- [By Monica Gerson]
Zions Bancorporation (NASDAQ: ZION) is projected to post its quarterly earnings at $0.39 per share on revenue of $576.49 million.
Crane Co. (NYSE: CR) is expected to post its quarterly earnings at $0.86 per share on revenue of $644.60 million.
- [By Matthew Briar]
Earlier this week, Vitality Biopharma Inc (OTCMKTS:VBIO) threw its hat into the opioid-replacement ring, pointing out its work with the highly-flexible cannabis plant could easily be applied to kill severe pain. As Vitality Biopharma CEO Robert Brooke put it, “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”
It couldn’t have been better scripted for VBIO shareholders. On Friday of this week, Fox News posted “Medical marijuana programs may help cut opioid use,” underscoring many of the things Brooke pointed out.
The Fox News commentary served up some encouraging statistics on the potential of medical marijuana and cannabis as an alternative pain treatment. Specifically, the article recited data from a contribution to the American Journal of Public Health, saying “The researchers found that the rates of opioid use decreased in adults ages 21 to 40 in states that had legalized medical marijuana and where residents with prescriptions could obtain cannabis from dispensaries or grow their own, compared to states that had legalized medical marijuana but did not yet have an operational program for people to obtain it.”
It points to the distinct reality that (1) not every opioid user want to use it, and (2) there’s a pain-killing upside to medical marijuana. And it’s worth noting the research focused on the more traditional forms of medical marijuana, and not as a prescription-dispended pill or injection. In a more refined form, it may offer treatment options for an even greater number of people.
At the heart of Vitality Biopharma’s future – and pipeline – is a superior science.
In short, the same basic molecular formula that makes cannabis an incredibly useful basis for drug creation is made even bett
- [By Matthew Briar]
When many investors think of medical marijuana — real cannabinoid drugs as opposed to a food or drink with some sort of marijuana plant listed as an ingredient — companies like GW Pharmaceuticals PLC (NASDAQ:GWPH) and Insys Therapeutics Inc (NASDAQ:INSY) come to mind. That’s not unreasonable. Insys Therapeutics’ dronabinol oral solution, Syndros(tm), is the first FDA- approved orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol… a pharmaceutical version of tetrahydrocannabinol (“THC”). Syndros treats anorexia-driven weight loss for AIDS patients. n the meantime, GW Pharmaceuticals’ cannabinoid-based Sativex has already been approved in several countries as a way of reducing muscle spasticity for multiple sclerosis patients. It’s also being tried as a pain-control drug for cancer patients, demonstrating not just the efficacy of cannabinoids, but the diversity of what the can do.
Each company’s portfolio and pipeline are promising, as are cannabinoids in general. A yound and hungry outfit called Vitality Biopharma Inc (OTCMKTS:VBIO), though, may take the science of cannabinoid to the next proverbial level.
Vitality Biopharma’s work so far has aimed to make cannabidiol the next generation of cannabinoid drugs.
Cannabidiol is a non-psychotropic (meaning it doesn’t get you “high) form of cannabis, and has demonstrated therapeutic effects for major neurological conditions like rare seizure disorders, and also as a way of treating symptoms of multiple sclerosis. Vitality Biopharma’s prodrugs [drugs that are converted into their effective form after being processed in the body] could exert the same therapeutic effects. But, Vitality’s drugs could do this better than most cannabinoids currently do.
How so? Broadly speaking, and as was noted, Vitality Biopharma’s work to-date has focused on turning cannabidiol into a prodrug, or a drug that doesn’t become its final, active form until it’s
- [By James E. Brumley]
When most most investors thik of medical marijuana — actual cannabinoid drugs rather than just an edible that names marijuana plant as an ingredient — companies like GW Pharmaceuticals PLC (NASDAQ:GWPH) and Insys Therapeutics Inc (NASDAQ:INSY) come to mind. And, that’s largely as it should be. Insys Therapeutics’ dronabinol oral solution, Syndros(tm), is the FDA’s first-ever approved orally-administered liquid formula of the pharmaceutical cannabinoid dronabinol, which is a pharmaceutical version of tetrahydrocannabinol (“THC”). (Syndros treatment for anorexia-driven weight loss in patients with AIDS.) And, GW Pharmaceuticals’ cannabinoid-based Sativex is already approved in several countries as a means of controlling muscle spasticity for multiple sclerosis patients. It’s also being tried as a means of pain-control in cancer patients.
Both companies’ portfolios and pipelines are promising, as are cannabinoid in general. An up-and-coming company called called Vitality Biopharma Inc (OTCMKTS:VBIO), however, may well take the science of cannabis to a whole new level.
Vitality Biopharma’s work so far has been focused on the use of cannabidiol as a means of creating better drugs.
Cannabidiol is a non-psychotropic derivative of cannabis, which has shown therapeutic effects for serious neurological conditions including rare seizure disorders, and for alleviating symptoms of multiple sclerosis. Vitality Biopharma’s prodrugs (drug that are converted into their effective form after being processed in the body) could exert the same beneficial therapeutic effects. Howver, they could do so better than most rival cannabinoid drugs do.
How so? Part of the overarching answer is, Vitality Biopharma’s work has been in turning cannabidiol into a prodrug. This allows for targeted delivery within the body, even to the brain. Perhaps the biggest edge cannabidiol-based drugs have over cannabinoids, though, is that they’re non-psychotr
- [By James E. Brumley]
In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.
We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.
As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.
There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.
It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.
Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo
- [By James E. Brumley]
Are you an investor interested in learning more about Vitality Biopharma Inc (OTCMKTS:VBIO)? Or, are you looking to take your first look at VBIO? A SeeThruEquity research report posted in August not only has you covered, it underscores all of its hidden bullishness. The report also explains a very impressive target price for Vitality Biopharma shares. In short, the research outfit now believes the stock will see $2.00 per share sooner than later, based on its pipeline and potential market penetration. That’s 38% higher than its current value.
- [By Bryan Murphy]
In early September, Vitality Biopharma Inc (OTCMKTS:VBIO) unofficially entered the opioid-replacement race when CEO Robert Brooke highlighted the company’s work that could turn the highly-flexible cannabis plant into a drug that could treat severe pain just as well as opioids could. As Brooke explained it, “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”